U.S. Markets close in 12 mins

AVEO Pharmaceuticals, Inc. (AVEO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
4.5764+0.0164 (+0.36%)
As of 3:47PM EDT. Market open.

AVEO Pharmaceuticals, Inc.

One Broadway
14th Floor
Cambridge, MA 02142
United States
617-588-1960
http://www.aveooncology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael P. BaileyCEO, Pres & Director854.4kN/A1965
Ms. Karuna RubinSr. VP & Gen. Counsel473.37kN/A1977
Dr. Michael N. NeedleChief Medical Officer597.64kN/A1960
Mr. Erick J. Lucera CPA, CFAChief Financial OfficerN/AN/A1968
Ms. Lisa M. BruneauVP of Financial Accounting & Reporting and TreasurerN/AN/A1967
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical needs. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase III TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. AVEO Pharmaceuticals, Inc. has collaboration and license agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Corporate Governance

AVEO Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.